Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

医学 荟萃分析 胰高血糖素样肽1受体 内科学 2型糖尿病 糖尿病 梅德林 重症监护医学 生物信息学 药理学 兴奋剂 受体 内分泌学 生物 政治学 法学
作者
Naveed Sattar,Matthew M.Y. Lee,Søren Lund Kristensen,Kelley R. Branch,Stefano Del Prato,Nardev S. Khurmi,Carolyn S.P. Lam,Renato D. Lópes,John J.V. McMurray,Richard E. Pratley,Julio Rosenstock,Hertzel C. Gerstein
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:9 (10): 653-662 被引量:1490
标识
DOI:10.1016/s2213-8587(21)00203-5
摘要

Summary

Background

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes.

Methods

We did a meta-analysis, including new data from AMPLITUDE-O, using a random effects model to estimate overall hazard ratio (HR) for MACE; its components; all-cause mortality; hospital admission for heart failure; a composite kidney outcome consisting of development of macroalbuminuria, doubling of serum creatinine, or at least 40% decline in estimated glomerular filtration rate (eGFR), kidney replacement therapy, or death due to kidney disease; worsening of kidney function, based on eGFR change; and odds ratios for key safety outcomes (severe hypoglycaemia, retinopathy, pancreatitis, and pancreatic cancer). We also examined MACE outcome in patient subgroups on the basis of MACE incidence rates in the placebo group, presence or absence of cardiovascular disease, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age, and eGFR. We searched PubMed for eligible trials reporting MACE (ie, cardiovascular death, myocardial infarction, or stroke), up to June 9, 2021. We meta-analysed data from published randomised placebo-controlled trials testing either injectable or oral GLP-1 receptor agonists in patients with type 2 diabetes. We restricted the search to trials of more than 500 patients with a primary outcome that included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This meta-analysis was registered on PROSPERO, CRD42021259711.

Findings

Of 98 articles screened, eight trials comprising 60 080 patients fulfilled the prespecified criteria and were included. Overall, GLP-1 receptor agonists reduced MACE by 14% (HR 0·86 [95% CI 0·80–0·93]; p<0·0001), with no significant heterogeneity across GLP-1 receptor agonist structural homology or eight other examined subgroups (all pinteraction≥0·14). GLP-1 receptor agonists reduced all-cause mortality by 12% (HR 0·88 [95% CI 0·82–0·94]; p=0·0001), hospital admission for heart failure by 11% (HR 0·89 [95% CI 0·82–0·98]; p=0·013), and the composite kidney outcome by 21% (HR 0·79 [95% CI 0·73–0·87]; p<0·0001), with no increase in risk of severe hypoglycaemia, retinopathy, or pancreatic adverse effects. In sensitivity analyses removing the only trial restricted to patients with an acute coronary syndrome (ELIXA), all benefits marginally increased, including the outcome of worsening of kidney function, based on eGFR change (HR 0·82 [95% CI 0·69–0·98]; p=0·030).

Interpretation

GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MACE components, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.

Funding

None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaobai发布了新的文献求助10
1秒前
西红柿完成签到,获得积分10
1秒前
大模型的应助被开朗紫采纳,获得10
1秒前
研友_ndvWy8完成签到,获得积分10
2秒前
3秒前
4秒前
5秒前
莓莓发布了新的文献求助10
6秒前
FG完成签到,获得积分10
6秒前
爆米花的应助被简单山水采纳,获得10
6秒前
上官若男的应助被雾潋采纳,获得10
7秒前
Kiss完成签到,获得积分10
9秒前
cdercder的应助被fzt采纳,获得10
9秒前
9秒前
GBY完成签到,获得积分10
10秒前
LIUJIAWEI发布了新的文献求助10
11秒前
Maestro_S的应助被一呆采纳,获得10
11秒前
GBY发布了新的文献求助10
12秒前
BINBIN完成签到,获得积分10
14秒前
顺利的盼曼完成签到 ,获得积分10
15秒前
我的djwhjja发布了新的文献求助10
15秒前
1234完成签到,获得积分10
17秒前
creach完成签到,获得积分10
17秒前
科研通AI6.3的应助被WZJ采纳,获得10
18秒前
悦耳凤灵完成签到,获得积分10
19秒前
Jasper的应助被李飞龙采纳,获得10
19秒前
领导范儿的应助被xiaobai采纳,获得10
22秒前
Jun的应助被GBY采纳,获得10
22秒前
22秒前
23秒前
我的djwhjja完成签到,获得积分10
23秒前
23秒前
光亮发卡发布了新的文献求助10
23秒前
李健的小迷弟的应助被yosh采纳,获得10
23秒前
creach发布了新的文献求助10
24秒前
pp完成签到,获得积分10
24秒前
24秒前
不爱喝酒的应助被interest-li采纳,获得10
25秒前
852的应助被wwwwwl采纳,获得30
25秒前
Owen的应助被interest-li采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568